Compare CREX & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CREX | MCRB |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 41.2M |
| IPO Year | 2015 | 2015 |
| Metric | CREX | MCRB |
|---|---|---|
| Price | $2.61 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 25.4K | ★ 47.4K |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,437,000.00 | $789,000.00 |
| Revenue This Year | $81.98 | N/A |
| Revenue Next Year | $14.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.61 | N/A |
| 52 Week Low | $2.22 | $3.90 |
| 52 Week High | $4.42 | $29.98 |
| Indicator | CREX | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 34.20 |
| Support Level | N/A | N/A |
| Resistance Level | $3.74 | $5.80 |
| Average True Range (ATR) | 0.21 | 0.34 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 7.81 | 7.80 |
Creative Realities Inc, along with its subsidiaries, is engaged in providing digital marketing technology & solutions to world-wide retail companies, luxury and other individual retail brands, advertising networks, outdoor clients, enterprises, and other organizations. The company operates in one reportable segment, marketing technology solutions. It offers solutions related to digital merchandising systems, omnichannel customer engagement systems, interactive digital shopping assistants, advisors and kiosks, and high-end audio-visual networks, along with marketing technologies such as mobile, social media, point-of-sale transactions, beaconing, and web-based media. Geographically, the company generates maximum revenue from the United States, and the rest from Canada.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.